Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02614209 · ClinicalTrials.gov registry record

Blood Collection of Patient Presenting in the ED and Prescribed a BNP

A clinical trial, sponsored by Fujirebio Diagnostics.

Completed
Registry status
400
Enrollment target

NCT02614209: Completed study, sponsored by Fujirebio Diagnostics.

NCT02614209 is a clinical trial that has completed, run by Fujirebio Diagnostics. The registered enrollment target is 400 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02614209 has completed, sponsored by Fujirebio Diagnostics.

COMPLETED
Registry status
400 participants
Enrollment target

Study Summary

Plasma specimen collected from patients presenting in the Emergency Department (ED) with or without Heart Failure (HF) and prescribed a BNP.

Primary Outcome

400 subjects

Interventions

  • DEVICE In Vitro diagnostic tests

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2015-05
Est. Completion 2016-08
Fujirebio Diagnostics

13 total trials

What the finished NCT02614209 record still lists

NCT02614209 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 1 intervention - of which In Vitro diagnostic tests is the first listed.

NCT02614209 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02614209 about?

NCT02614209 is a clinical study titled "Blood Collection of Patient Presenting in the ED and Prescribed a BNP". Plasma specimen collected from patients presenting in the Emergency Department (ED) with or without Heart Failure (HF) and prescribed a BNP.

What is the current status of trial NCT02614209?

This trial is currently completed. The enrollment target is 400 participants. The study started on 2015-05. Estimated completion is 2016-08.

What interventions are being tested in trial NCT02614209?

The interventions under investigation include: In Vitro diagnostic tests (DEVICE).

Who is sponsoring clinical trial NCT02614209?

This trial is sponsored by Fujirebio Diagnostics, which has 13 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01665326 · 400 participants

    Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

  • NCT02108054 · 400 participants · NA

    Behavioral and Functional Task Development, Implementation, and Testing

  • NCT02216500 · 400 participants · NA

    Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

  • NCT02250352 · 400 participants

    Core Biopsies for Establishing a Breast Tumor Tissue Repository

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02614209, the US trial registry maintained by the National Library of Medicine. NCT02614209 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.